Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Product and Product-Related Service Revenue from Sale of Instruments and Consumables

Product and Product-related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three months ended March 31, 2020 and 2019 as follows:

	Three Months Ended March 31,
	2020		2019
Product revenue:
Instruments	$	234,625	$	140,416
Consumables		545,939		400,818
Total product revenue		780,564		541,234
Product-related services revenue:
Custom RUO assay design		629,182		367,859
RUO sample processing		578,391		1,753,412
Total product-related services revenue		1,207,573		2,121,271
Total product and product-related services revenue	$	1,988,137	$	2,662,505

Schedule of Collaborative Development Services

Collaborative Development Services Revenue

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606, Revenue from Contracts with Customers and ASC 808, Collaborative Arrangements to determine the appropriate recognition of revenue under our collaborative research, development and commercialization agreements that contain multiple elements. For the three months ended March 31, 2020 and 2019, collaborative development services revenue was generated through statements of work entered into under the Governing Agreement with QML as follows:  

	Three Months Ended March 31,
	2020		2019
Collaborative development services	$	237,337	$	540,320

Schedule of Changes in Contract Liability

Changes in the Company’s contract liability were as follows as of the dates indicated:

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2020	$	95,148		$	66,216		$	438,090		$	599,454
Deferral of revenue		229,927			300,000			62,329			592,256
Recognition of deferred revenue		(214,712	)		(366,216	)		(30,119	)		(611,047	)
Balance at March 31, 2020	$	110,363		$	—		$	470,300		$	580,663

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2019	$	116,547		$	50,000		$	244,400		$	410,947
Deferral of revenue		50,667			11,685			48,327			110,679
Recognition of deferred revenue		(36,544	)		(11,685	)		(117,695	)		(165,924	)
Balance at March 31, 2019	$	130,670		$	50,000		$	175,032		$	355,702